Vestra is composed of an active ingredient known as Reboxetine and other inactive components. Vestra (Reboxetine) is a type of an antidepressant drug which is known as Norepinephrine Reuptake Inhibitor (NRI). It is used for the treatment of depressive illness and major depression. It works on the chemical compound, a neurotransmitter known as Norepinephrine which acts as chemical messengers between the nerve cells in the brain. The release of norepinephrine from the nerve cells in the brain lightens the mood. Re-absorption of it in nerve cells no longer has the effects on mood. When there is depression, it is thought that there is a decrease amount of release of norepinephrine from nerve cells. Vestra (Reboxetine) prevents norepinephrine from getting reabsorbed into the nerve cells and helps in prolonged lightening mood. This way Vestra (Reboxetine) helps in relieving the depression. Vestra (Reboxetine) comes in a form of tablets for oral administration in two different strengths of 2mg and 4mg.

For adults the recommended starting dose of Vestra (Reboxetine) is 4mg twice a day, i.e. 8mg a day in total. If there is an incomplete clinical response after 3 weeks of treatment, the dose can be increased to 10mg a day.
For elderly patients above 65 years of age, the recommended starting dose of Vestra (Reboxetine) is 2mg twice a day, i.e. 4mg a day in total. If there is an incomplete clinical response after 3 weeks of treatment, the dose can be increased to 6mg a day.
For patients with hepatic and/or renal problems, the recommended starting dose of Vestra (Reboxetine) is 2mg twice a day, i.e. 4mg a day in total. Depending on the patient’s tolerance the dosage can be increased later.
Only after two to four weeks of treatment the benefits of Vestra (Reboxetine) can be seen.

Side effects indicated using Vestra (Reboxetine) medication are insomnia, increased sweating, dizziness, hypotension, paraesthesia, impotence, urinary tract infections, dysuria, dry mouth, constipation, tachycardia, vertigo, urinary retention, anxiety, loss of appetite, loss of libido, pain on ejaculation, increased orgasm intensity and pre-matured or quickened ejaculation.
Impotence is mainly found in patients taking more than 8mg a day.

There are some medications when taken concurrently with Vestra (Reboxetine) may prevent the breakdown of reboxetine by the liver and increase the risk of its side effects. The medications interacted with are azole antifungals, fluvoxamine, macrolide antibiotics and nefazodone.
Vestra (Reboxetine) and ergot derivatives when taken concurrently may cause hypertension.
Vestra (Reboxetine) and diuretics when taken concurrently may decrease the level of potassium in blood.
Vestra (Reboxetine) and Mono-Amine Oxidase Inhibitor (MAOI) are not recommended to be taken concurrently.
Vestra (Reboxetine) and sibutramine are not recommended to be taken concurrently.

Vestra (Reboxetine) is used for the treatment of clinical depression, panic disorder and attention-deficit hyperactivity disorder (ADHD).

Store Vestra (Reboxetine) tablets at a temperature preferably below 25°C (77°F), but can be stored between 15°-30°C (59°-86°F). Protect from direct sunlight, heat and moisture. Keep away from children and pets.

Nursing mothers and pregnant women should take precautions and consult the physician before taking the drug.
Vestra (Reboxetine) may cause the amount of sodium in the blood to drop. The symptoms are muscle twitching, drowsiness and confusion. Elderly patients should be more cautious as they are more prone to these symptoms.
Patient should be cautious while driving and operating machineries taking while in treatment.
Patients with history of urinary retention, glaucoma, enlarged prostate gland, seizures, cardiac problem; decreased hepatic and renal functions should take precautions.
For children under 18 years, Vestra (Reboxetine) is not recommended as it may increase the risk of anger, aggression and suicidal thoughts.